Introduction

For decades, medicine in India has operated on a broadly uniform model. A patient presents with a condition, a standard protocol is applied, and the outcome is hoped to follow. This approach has saved countless lives. But it has also left an equally significant number of patients with treatments that worked partially, caused adverse effects, or simply did not work at all. The reason, increasingly understood by the global medical community, is that human beings are not biologically identical. Their genes differ, their environments differ, their microbiomes differ, and these differences profoundly shape how disease develops and how the body responds to treatment.

Precision medicine, also called personalised medicine, is built on the recognition of this biological individuality. It uses a patient's unique molecular and genetic profile to guide clinical decisions, select the right drug at the right dose for the right person, and ideally prevent disease before it manifests. In high-income countries, this approach has already transformed oncology, cardiology, and rare disease management. The question for India, with its vast population, extraordinary genetic diversity, and healthcare infrastructure that spans world-class private hospitals to resource-limited rural centres, is whether precision medicine can move from a niche offering to a practical, scalable reality.

The answer, as this article explores, is nuanced, encouraging, and still very much in progress.

Understanding Precision Medicine: The Science Behind Personalised Treatment

Precision medicine is not a single technology or therapy. It is a framework that integrates multiple layers of biological information to make clinical decisions. The core inputs include:

• Genomics: The study of a patient's entire genetic sequence to identify disease-causing mutations, inherited risk factors, and pharmacogenomic markers that predict drug response.
• Proteomics and metabolomics: Analysis of proteins and metabolites to understand disease activity at a molecular level.
• Epigenomics: How environmental and lifestyle factors alter gene expression without changing the DNA sequence itself.
• Clinical data and lifestyle information: Including diet, physical activity, exposure history, and comorbidities.

When these data streams are integrated, clinicians can move beyond diagnosis-based treatment to treatment that is tailored to the individual biology of the patient. In oncology, for example, identifying a specific BRCA mutation in a breast cancer patient opens access to PARP inhibitor therapy that would be ineffective in a patient without that mutation. In pharmacology, identifying that a patient carries a CYP2D6 variant that affects drug metabolism can prevent dosing errors that lead to adverse reactions.

The tools enabling this include next-generation sequencing (NGS), companion diagnostics, liquid biopsies, and increasingly, artificial intelligence platforms that can analyse large genomic and clinical datasets to generate treatment recommendations.

The Indian Context: Why Precision Medicine Matters More Here Than Almost Anywhere

India carries one of the world's highest burdens of both communicable and non-communicable disease. The country accounts for over 1.3 million new cancer cases annually, according to data from the National Cancer Registry Programme. Cardiovascular disease, diabetes, tuberculosis, and rare genetic disorders collectively affect hundreds of millions of Indians. Yet for all of this, Indian patients have largely been treated using protocols developed primarily on Western, predominantly Caucasian, patient populations.

This matters because the Indian population is genetically distinct. India's genetic diversity is extraordinary, shaped by thousands of years of endogamy, geographic isolation, and population stratification. Variants in drug-metabolising genes, disease susceptibility loci, and pharmacogenomic markers that are well-characterised in European populations may behave differently, or may be entirely different, in South Asian, Northeast Indian, or Dravidian population groups. Treating these patients with protocols calibrated for a different genetic population introduces inherent imprecision into the treatment itself.

The Genome India Project, launched by the Government of India and coordinated through the Department of Biotechnology, is directly addressing this gap. The project aims to sequence the genomes of ten thousand individuals representing India's diverse population to create a comprehensive Indian reference genome database. This dataset will eventually allow clinicians and researchers to understand which genetic variants are uniquely prevalent in Indian populations and how these variants affect disease risk and drug response. Institutions including the Centre for Cellular and Molecular Biology in Hyderabad and the Institute of Genomics and Integrative Biology in Delhi are leading this scientific effort.

Beyond the science, India has a second compelling reason to pursue precision medicine at scale. Drug toxicity and treatment failure carry enormous economic and human costs. If a cancer patient receives three ineffective chemotherapy regimens before reaching a targeted therapy that works, the cost to the patient, the healthcare system, and the outcome is significantly greater than if precision diagnostics had identified the right therapy at the outset. Precision medicine, at scale, could be a cost-efficiency strategy as much as a clinical one.

Where India Stands Today: Current Applications and Available Infrastructure

Precision medicine in India is no longer theoretical. It is happening, though unevenly distributed.

Oncology is the most advanced domain. Leading cancer centres, including Tata Memorial Hospital in Mumbai, AIIMS in New Delhi, Rajiv Gandhi Cancer Institute, Apollo Hospitals, and Manipal Hospitals, have integrated next-generation sequencing into their oncology workflows. Companion diagnostics for EGFR, ALK, KRAS, HER2, and PDL1 mutations are routinely used to guide lung, breast, and colorectal cancer treatment decisions. Liquid biopsy, which detects tumour DNA circulating in the blood, is available at select centres and is particularly valuable for monitoring treatment response and detecting early resistance.

Pharmacogenomics, the study of how genes affect drug response, is emerging in Indian clinical practice. Several hospitals now offer pharmacogenomic panels before initiating anticoagulant therapy with warfarin, psychiatric medications, or immunosuppressants after organ transplant. These panels reduce adverse drug events and improve dosing precision.

Rare genetic diseases represent another growing application. India has a significant burden of rare diseases, many of which are caused by single-gene mutations and are theoretically amenable to gene therapy or precision pharmacotherapy. The National Policy for Rare Diseases 2021 has provided some regulatory and financial framework, and specialist centres for rare disease management are expanding.

Artificial intelligence is entering the diagnostic and treatment recommendation space. Indian healthtech companies and hospital groups are piloting AI platforms that integrate pathology images, genomic data, and clinical histories to generate precision treatment recommendations. Companies like MedGenome, Strand Life Sciences, and Theragen Bio have established genomic testing infrastructure in India that feeds into clinical decision-making.

The Barriers: What Is Holding Precision Medicine Back in India

Despite this progress, precision medicine faces structural, economic, and systemic barriers that prevent it from reaching its potential in India.

Cost is the most immediate challenge. Comprehensive genomic sequencing remains expensive for the majority of Indian patients. While the cost of whole-genome sequencing has fallen dramatically globally, it remains financially out of reach for patients without insurance coverage or the means to pay out of pocket. Most government health insurance schemes, including Ayushman Bharat PM-JAY, do not yet cover genomic diagnostics. Until reimbursement frameworks include precision diagnostics, adoption will remain concentrated in private, urban, and affluent settings.

Infrastructure inequality is equally significant. The genomics and molecular diagnostics infrastructure required for precision medicine is concentrated in metropolitan cities. Patients in Tier 2 cities and rural districts have no meaningful access to NGS-based diagnostics or molecular oncology. This creates a two-tier system where the benefits of precision medicine accrue only to those with geographic and economic proximity to large urban hospitals.

Data gaps in Indian genomics remain a scientific constraint. Without a large, representative Indian genomic reference dataset, it is impossible to interpret variants of unknown significance in Indian patients accurately. The Genome India Project is addressing this, but comprehensive data will take years to generate and validate.

Regulatory frameworks around genomic data, data privacy, and clinical use of AI-driven precision tools are still evolving. The Digital Personal Data Protection Act 2023 provides a foundation for health data governance, but specific guidelines around genomic data sharing, consent frameworks, and clinical validation requirements for precision diagnostics are not yet fully developed.

Physician awareness and training present an additional challenge. Implementing precision medicine requires clinicians who understand genomic medicine, can interpret molecular reports, and can integrate genomic information into treatment planning. Most medical graduates in India have limited formal training in genomics or pharmacogenomics. Bridging this knowledge gap requires curriculum reform, continuous medical education, and specialist training programmes.

The Path Forward: What Will Make Precision Medicine Practical in India

Several developments, already underway, are likely to accelerate the transition of precision medicine from selective availability to broader clinical practice in India.

The maturation of the Genome India Project will produce an invaluable scientific foundation. As the Indian reference genome dataset grows, the ability to interpret genomic variants in Indian patients will improve significantly, increasing both the accuracy and clinical utility of genomic testing.

Digital health infrastructure under the Ayushman Bharat Digital Mission (ABDM) is creating a framework for longitudinal health data collection at scale. When patient records, diagnostic data, and treatment outcomes are systematically linked through a health ID system, the data-richness required to power AI-assisted precision medicine recommendations becomes achievable at a population level.

The Indian Council of Medical Research (ICMR) has been publishing guidelines on pharmacogenomics and genomic medicine, and its role in setting evidence-based clinical frameworks for precision diagnostics is critical to building trust and standardisation in this space.

Cost reduction through technology scale and domestic manufacturing of diagnostic reagents and sequencing instruments is also expected to improve affordability over time. Several Indian startups are working to develop lower-cost NGS platforms and bioinformatics tools suited to Indian healthcare budgets.

Platforms like Medicircle, which bridge healthcare experts and the broader public, have a meaningful role to play in this transition. Expert voices in genomics, oncology, and personalised medicine need channels to reach clinicians, patients, and policymakers with accurate, accessible, and up-to-date information. Informed patients ask better questions, seek appropriate testing, and are more likely to engage productively with the emerging precision medicine ecosystem.

Conclusion

Precision medicine in India is no longer a distant aspiration. It is an emerging clinical reality, advancing most visibly in oncology and pharmacogenomics, supported by government initiatives like the Genome India Project and the digital health infrastructure of ABDM, and driven by a growing base of Indian genomics research and healthtech innovation. The barriers are real and significant, from cost and infrastructure gaps to data limitations and regulatory maturation. But the direction of travel is clear.

For Indian patients, the promise of treatment calibrated to their unique biology rather than a population average is not a luxury. Given India's extraordinary genetic diversity and the documented limitations of applying Western-derived treatment protocols to Indian patients, precision medicine is a clinical and scientific necessity. The task ahead is to ensure that the benefits of personalised treatment reach not just the fortunate few in metropolitan hospitals, but progressively wider, more equitable, and more inclusive circles of patients across India.

Frequently Asked Questions

Q1: What is precision medicine and how is it different from conventional treatment?

Precision medicine tailors medical treatment to the individual characteristics of each patient, including their genetic profile, lifestyle, and environment. Unlike conventional medicine, which applies one standard treatment to all patients with the same diagnosis, precision medicine uses genomic and molecular data to select the most effective therapy for each person.

Q2: Is precision medicine available in India today?

Yes, precision medicine is available in India, though primarily at large tertiary care centres and select private hospitals in cities like Mumbai, Delhi, Bengaluru, Chennai, and Hyderabad. Oncology is the most advanced area, with targeted therapies and companion diagnostics increasingly accessible. Widespread availability across Tier 2 and Tier 3 cities remains limited.

Q3: What role does genomics play in precision medicine in India?

Genomics is the foundation of precision medicine. In India, institutions like the Centre for Cellular and Molecular Biology and IGIB are building population-level genomic datasets specific to Indian genetic diversity. These datasets help identify disease risk, drug response variations, and targeted treatment possibilities relevant to the Indian population.

Q4: How much does precision medicine or genetic testing cost in India?

Costs vary widely. Basic genetic panels may range from a few thousand rupees to over one lakh rupees for comprehensive whole-genome sequencing. Targeted cancer therapies linked to precision medicine can run significantly higher. Cost remains one of the primary barriers to wide adoption, though prices are gradually declining as technology scales.

Q5: What is the Government of India doing to support precision medicine?

The Government of India launched the Genome India Project to map the genetic diversity of the Indian population. This initiative is creating a reference dataset that supports population-specific precision medicine research. Additionally, the ABDM digital health infrastructure and NITI Aayog's health data policies are laying the groundwork for data-driven personalised healthcare at scale.

Resources

1. Indian Council of Medical Research (ICMR): Guidelines, publications, and policy frameworks on genomic medicine and pharmacogenomics in India.
2. Genome India Project, Department of Biotechnology, Government of India: National initiative to sequence and map the genetic diversity of the Indian population.
3. National Cancer Registry Programme (NCRP), ICMR: Cancer incidence and burden data for India, used to understand the clinical need for precision oncology.
4. Ayushman Bharat Digital Mission (ABDM): Framework for India's digital health infrastructure, foundational to data-driven personalised medicine.
5. World Health Organization (WHO): Global frameworks and evidence on precision medicine, genomics, and health equity in low- and middle-income countries.

Interlinking Keywords

Genome India Project, precision oncology in India, personalised medicine, pharmacogenomics, Ayushman Bharat Digital Mission, next-generation sequencing, targeted cancer therapy, ICMR genomics guidelines, rare diseases India, AI in healthcare India

Last medically reviewed by:

Editorial and Medical Review Team, Medicircle on 4, September 2026

Medical Disclaimer:

This article is intended for general awareness and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Readers are advised to consult a qualified medical professional for any health-related concerns or before making any decisions regarding their healthcare.